Ontology highlight
ABSTRACT: Background
Levels of thyroid-stimulating hormone (TSH) are believed to reflect degree of disease in patients with hypothyroidism, and normalization of levels is the treatment goal. However, despite adequate levels of TSH after starting levothyroxine (LT4) therapy, 5-10% of hypothyroid patients complain of persisting symptoms with a significant negative impact on quality of life. This indicates that TSH is not an optimal indicator of intracellular thyroid hormone effects in all patients. Our aim was to investigate different effects of LT3 and LT4 monotherapy on other biomarkers of the thyroid signaling pathway, in addition to adverse effects, in patients with residual hypothyroid symptoms.Methods
Fifty-nine female hypothyroid patients, with residual symptoms on LT4 monothera
SUBMITTER: Bjerkreim BA
PROVIDER: S-EPMC9095395 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature